Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q15269680> ?p ?o }
Showing triples 1 to 36 of
36
with 100 triples per page.
- Q15269680 subject Q7335338.
- Q15269680 subject Q8297683.
- Q15269680 subject Q8533683.
- Q15269680 subject Q8878163.
- Q15269680 subject Q8969064.
- Q15269680 abstract "Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib. Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea. Radotinib completed a multi-national Phase II clinical trial study in 2012 and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication. Its mechanism of action involves inhibition of the Bcr-Abl tyrosine kinase and of platelet-derived growth factor receptor (PDGFR).".
- Q15269680 atcPrefix "None".
- Q15269680 casNumber "926037-48-1".
- Q15269680 iupacName "4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide".
- Q15269680 pubchem "16063245".
- Q15269680 thumbnail Radotinib.svg?width=300.
- Q15269680 wikiPageWikiLink Q1129111.
- Q15269680 wikiPageWikiLink Q177094.
- Q15269680 wikiPageWikiLink Q309510.
- Q15269680 wikiPageWikiLink Q3271540.
- Q15269680 wikiPageWikiLink Q4875411.
- Q15269680 wikiPageWikiLink Q7202242.
- Q15269680 wikiPageWikiLink Q729735.
- Q15269680 wikiPageWikiLink Q7335338.
- Q15269680 wikiPageWikiLink Q824258.
- Q15269680 wikiPageWikiLink Q8297683.
- Q15269680 wikiPageWikiLink Q8533683.
- Q15269680 wikiPageWikiLink Q8878163.
- Q15269680 wikiPageWikiLink Q8969064.
- Q15269680 atcPrefix "None".
- Q15269680 casNumber "926037".
- Q15269680 iupacName "4".
- Q15269680 pubchem "16063245".
- Q15269680 type ChemicalSubstance.
- Q15269680 type Drug.
- Q15269680 type ChemicalObject.
- Q15269680 type Thing.
- Q15269680 type Q8386.
- Q15269680 comment "Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib. Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea and is co-marketed by Daewoong Pharmaceutical Co.".
- Q15269680 label "Radotinib".
- Q15269680 depiction Radotinib.svg.